These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 20392512)

  • 1. Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model.
    Shindo N; Fujisawa T; Sugimoto K; Nojima K; Oze-Fukai A; Yoshikawa Y; Wang X; Yasuda O; Ikegami H; Rakugi H
    J Hepatol; 2010 Jun; 52(6):903-12. PubMed ID: 20392512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis.
    Musso G; Gambino R; Cassader M
    J Nutr Biochem; 2010 Sep; 21(9):834-40. PubMed ID: 19733470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
    García-Monzón C; Lo Iacono O; Mayoral R; González-Rodríguez A; Miquilena-Colina ME; Lozano-Rodríguez T; García-Pozo L; Vargas-Castrillón J; Casado M; Boscá L; Valverde AM; Martín-Sanz P
    J Hepatol; 2011 Jan; 54(1):142-52. PubMed ID: 20888662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease.
    Pereira IV; Stefano JT; Oliveira CP
    Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):245-51. PubMed ID: 21476919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis.
    Perlemuter G; Sabile A; Letteron P; Vona G; Topilco A; Chrétien Y; Koike K; Pessayre D; Chapman J; Barba G; Bréchot C
    FASEB J; 2002 Feb; 16(2):185-94. PubMed ID: 11818366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R; Cassader M; Pagano G; Durazzo M; Musso G
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice.
    Lettéron P; Sutton A; Mansouri A; Fromenty B; Pessayre D
    Hepatology; 2003 Jul; 38(1):133-40. PubMed ID: 12829995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.
    Matsuzawa N; Takamura T; Kurita S; Misu H; Ota T; Ando H; Yokoyama M; Honda M; Zen Y; Nakanuma Y; Miyamoto K; Kaneko S
    Hepatology; 2007 Nov; 46(5):1392-403. PubMed ID: 17929294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
    Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
    Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V; Lucero D; Macri EV; Cacciagiú L; Gamba CA; Miksztowicz V; Berg G; Wikinski R; Friedman S; Schreier L
    Ann Nutr Metab; 2010; 56(3):198-206. PubMed ID: 20203480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
    Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
    J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?
    Ariz U; Mato JM; Lu SC; Martínez Chantar ML
    Methods Mol Biol; 2010; 593():109-36. PubMed ID: 19957147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
    VerHague MA; Cheng D; Weinberg RB; Shelness GS
    Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.